Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its price objective hoisted by HC Wainwright from $70.00 to $75.00 in a research report report published on Friday morning, The Fly reports. Several other research analysts also recently commented on BPMC. SVB Securities dropped their target price on shares of Blueprint Medicines from $45.00 to $38.00 in […]
Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) were up 9.7% on Thursday . The company traded as high as $57.79 and last traded at $56.93. Approximately 369,365 shares changed hands during trading, a decline of 33% from the average daily volume of 548,409 shares. The stock had previously closed at $51.88. Wall Street […]
Blueprint Medicines (NASDAQ:BPMC – Get Rating) is scheduled to announce its earnings results before the market opens on Thursday, May 4th. Analysts expect the company to announce earnings of ($2.61) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link. Blueprint Medicines (NASDAQ:BPMC […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) – Equities researchers at Wedbush lowered their Q1 2023 earnings per share estimates for Blueprint Medicines in a research report issued on Monday, April 24th. Wedbush analyst D. Nierengarten now anticipates that the biotechnology company will earn ($2.43) per share for the quarter, down from their previous forecast […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) has earned a consensus rating of “Hold” from the twenty brokerages that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has given a strong buy […]